GelrinC, a biodegradable hydrogel implant for treating cartilage defects in the knee, has received European CE mark approval
. This means it can be sold and marketed within the European community, which includes Germany.
Clinical trials and availability
- GelrinC was studied in Europe, including Germany, in a clinical trial with 50+ patients, and results suggested improvements in pain and function.
- An additional 30 patients are currently enrolled at 12 new sites in Europe, including Germany, Belgium, Poland, the Netherlands and Israel.
- It’s important to note that while GelrinC is CE mark-approved and available for use within the European Union, its availability to individual patients may depend on factors like:
- Specific clinical guidelines and recommendations in Germany.
- Individual patient eligibility criteria set by healthcare providers or research studies.
- Whether a patient’s insurance plan covers the treatment